Show simple item record

dc.contributor.advisorMayersohn, Michaelen
dc.contributor.authorLim, Fiona
dc.contributor.authorMayersohn, Michael
dc.date.accessioned2016-06-22T17:18:45Z
dc.date.available2016-06-22T17:18:45Z
dc.date.issued2015
dc.identifier.urihttp://hdl.handle.net/10150/614140
dc.descriptionClass of 2015 Abstracten
dc.description.abstractObjectives: To determine the effects of the dietary supplement, “Omega Q Plus ® Resveratrol” on cardiovascular health. More specifically, to review randomized controlled trials to determine the effects of resveratrol, coenzyme Q10, and omega-3-fatty acids on lipid levels and blood pressure. Methods: Randomized, double-blinded, placebo-controlled trials were searched using PubMed and Embase. Studies that assessed the effects of either resveratrol, coenzyme Q10, or omega-3 fatty acids on lipid levels and/or blood pressure in humans were included. Studies that did not use less than 1 gram of EPA and DHA were excluded. Data extraction and validity assessment was conducted by one reviewer; validity for trials were assessed using the Potential for Methodological Bias Assessment Tool (PBMAT). Results: A total of 24 studies were included; 11 for resveratrol, seven for coenzyme Q10, and six for omega-3 fatty acids, totaling to 1633 participants combined. Doses ranged from 8 mg to 3,000 mg of resveratrol per day, 100 mg to 200 mg of coenzyme Q10 per day, and 67 mg EPA + 33 mg DHA to 1944 mg EPA + 1686 mg DHA. Results across trials were inconsistent in regards to efficacy on lipid levels and blood pressure. Subjects with metabolic syndrome or hypertriglyceridemia seemed to benefit from omega-3 fatty acids through improvement in triglyceride levels, however effects with healthy patients were less clear. Conclusions: Overall, the interventions demonstrated mixed results in affecting lipid levels and blood pressure. No conclusions can be made at this point about the efficacy of Omega Q Plus® Resveratrol on cardiovascular health. Further research into these dietary supplements need to be conducted in order to assess their efficacy
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectsupplementsen
dc.subjectOmega Q Plus ® Resveratrolen
dc.subjectcardiovascularen
dc.subject.meshDietary Supplements
dc.subject.meshCardiovascular System
dc.subject.meshDrug Evaluation
dc.titleReviewing and Evaluating Claims for Dietary Supplements: Omega Q Plus ® Resveratrolen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
html.description.abstractObjectives: To determine the effects of the dietary supplement, “Omega Q Plus ® Resveratrol” on cardiovascular health. More specifically, to review randomized controlled trials to determine the effects of resveratrol, coenzyme Q10, and omega-3-fatty acids on lipid levels and blood pressure. Methods: Randomized, double-blinded, placebo-controlled trials were searched using PubMed and Embase. Studies that assessed the effects of either resveratrol, coenzyme Q10, or omega-3 fatty acids on lipid levels and/or blood pressure in humans were included. Studies that did not use less than 1 gram of EPA and DHA were excluded. Data extraction and validity assessment was conducted by one reviewer; validity for trials were assessed using the Potential for Methodological Bias Assessment Tool (PBMAT). Results: A total of 24 studies were included; 11 for resveratrol, seven for coenzyme Q10, and six for omega-3 fatty acids, totaling to 1633 participants combined. Doses ranged from 8 mg to 3,000 mg of resveratrol per day, 100 mg to 200 mg of coenzyme Q10 per day, and 67 mg EPA + 33 mg DHA to 1944 mg EPA + 1686 mg DHA. Results across trials were inconsistent in regards to efficacy on lipid levels and blood pressure. Subjects with metabolic syndrome or hypertriglyceridemia seemed to benefit from omega-3 fatty acids through improvement in triglyceride levels, however effects with healthy patients were less clear. Conclusions: Overall, the interventions demonstrated mixed results in affecting lipid levels and blood pressure. No conclusions can be made at this point about the efficacy of Omega Q Plus® Resveratrol on cardiovascular health. Further research into these dietary supplements need to be conducted in order to assess their efficacy


This item appears in the following Collection(s)

Show simple item record